Adicet Bio, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q3 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Adicet Bio, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q3 2019 to Q3 2024.
  • Adicet Bio, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $6.78M, a 21.9% increase year-over-year.
  • Adicet Bio, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $23.4M, a 19.3% increase year-over-year.
  • Adicet Bio, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $20.3M, a 18.3% increase from 2022.
  • Adicet Bio, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $17.1M, a 36.9% increase from 2021.
  • Adicet Bio, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $12.5M, a 138% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $23.4M $6.78M +$1.22M +21.9% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-06
Q2 2024 $22.2M $6M +$981K +19.5% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q1 2024 $21.2M $5.68M +$914K +19.2% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 $20.3M $4.91M +$661K +15.6% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-19
Q3 2023 $19.6M $5.56M +$1.37M +32.7% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 $18.2M $5.02M +$688K +15.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 $17.5M $4.77M +$415K +9.54% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 $17.1M $4.25M -$30K -0.7% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-19
Q3 2022 $17.2M $4.19M +$1.66M +65.7% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 $15.5M $4.34M +$1.68M +63% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 $13.8M $4.35M +$1.31M +43% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $12.5M $4.28M +$2.63M +160% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-15
Q3 2021 $9.88M $2.53M -$437K -14.7% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 $10.3M $2.66M +$2.31M +658% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-10
Q1 2021 $8.01M $3.04M +$2.74M +918% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 $5.26M $1.65M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-15
Q3 2020 $2.97M +$2.58M +659% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 $351K Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 $299K Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17
Q3 2019 $391K Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
* An asterisk sign (*) next to the value indicates that the value is likely invalid.